3C-AL

3C-AL
Clinical data
Other names	4-Allyloxy-3,5-dimethoxyamphetamine; 3,5-Dimethoxy-4-allyloxyamphetamine; α-Methylallylescaline; 3C-Allylescaline
Routes of; administration	Oral
Drug class	Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
Pharmacokinetic data
Duration of action	8–12 hours
Identifiers
	IUPAC name 1-[3,5-dimethoxy-4-[(prop-2-en-1-yl)oxy]phenyl]propan-2-amine;
CAS Number	214414-87-6 [EPA];
PubChem CID	44350107;
ChemSpider	23206506;
ChEMBL	ChEMBL123867;
CompTox Dashboard (EPA)	DTXSID50658378 ;
Chemical and physical data
Formula	C14H21NO3
Molar mass	251.326 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	180 to 181 °C (356 to 358 °F)
	SMILES C=CCOc1c(OC)cc(cc1OC)CC(N)C;
	InChI InChI=1S/C14H21NO3/c1-5-6-18-14-12(16-3)8-11(7-10(2)15)9-13(14)17-4/h5,8-10H,1,6-7,15H2,2-4H3; Key:ROINMNZLTKSBPR-UHFFFAOYSA-N;

3C-AL, also known as 4-allyloxy-3,5-dimethoxyamphetamine or as α-methylallylescaline (3C-allylescaline), is a psychedelic drug of the phenethylamine, amphetamine, and 3C families related to 3,4,5-trimethoxyamphetamine (TMA).^[3]^[1]^[2] It is the amphetamine (3C) analogue of allylescaline.^[3]^[1]^[2] The drug has a dose range of 15 to 30 mg orally and a duration of 8 to 12 hours.^[1]^[2] Its effects have been described as more visual than those of allylescaline.^[1] The drug is a potent partial agonist of the serotonin 5-HT_2A receptor and also interacts with other serotonin receptors and targets.^[2] The chemical synthesis of 3C-AL has been described.^[3]^[4] 3C-AL was described by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved), but he did not synthesize or test 3C-AL.^[3] Instead, Daniel Trachsel synthesized 3C-AL in 2002^[4] and described its properties and effects in 2013.^[1] The pharmacology of 3C-AL was studied in greater detail in 2021.^[2]

Quick facts Clinical data, Other names ...

See also